A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
B A C K G R O U N D: Treatment for TB is lengthy and toxic, and new regimens are needed. M E T H O D S: Participants with pulmonary drug-susceptible TB (DS-TB) were randomised to receive: 200 mg pretomanid (Pa, PMD) daily, 400 mg moxifloxacin (M) and 1500 mg pyrazinamide (Z) for 6 months (6Pa200MZ)...
Similar Items
-
Exchange rate exposure and crude oil price: The case of an emerging market
by: Hong M.C.; Chu E.Y.; Song S.I.
Published: (2018) -
Predicting organizational citizenship behavior through psychological ownership and job satisfaction in four-star hotels
by: Dewi I.G.A.M.; Riana I.G.; Kasuma J.; McGuinness E.; Maria S.; Darma D.C.
Published: (2021) -
Pre-emergence herbicidal activity and persistence of 2,4-di-tertbutylphenol in relation to soil types
by: Zain N.M.; Mat M.C.; Seng C.T.
Published: (2021) -
Development of iridium oxide sensor for surface pH measurement of a corroding metal under deposit
by: Rouhi J.; Kakooei S.; Ismail M.C.; Karimzadeh R.; Mahmood M.R.
Published: (2017) -
Vertical motion of Phuket Island (1994–2018) due to the Sumatra-Andaman mega-thrust earthquake cycle: impact on sea-level and consequences for coral reefs
by: Simons W.J.F.; Naeije M.C.; Brown B.E.; Niemnil S.; Pradit S.; Thongtham N.; Mustafar M.A.; Towatana P.; Darnsawasdi R.; Yucharoen M.; Visser P.N.A.M.
Published: (2019)